Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Quetiapine shows potential as monotherapy in bipolar depression

May 26, 2006

Three new mechanism-of-action studies begin for VNS Therapy

May 26, 2006

Newer antiepileptic drugs show potential in cyclic vomiting syndrome

May 26, 2006

Phase III study begins for Rylomine for severe postoperative orthopedic pain

May 26, 2006

Selective adenosine A2A receptors with potential in CNS disorders developed by Schering-Plough

May 25, 2006

Equasym for ADHD completes European mutual recognition procedure

May 25, 2006

FDA approval for Ionsys transdermal analgesic system

May 25, 2006

Screening begins in phase III trial of NRP-104 for adult ADHD

May 25, 2006

Vernalis presents preclinical, clinical update on BIIB-014 for Parkinson's disease

May 24, 2006

Adenosine A2A receptor antagonist MSX-3 shows activity in parkinsonian motor effects

May 24, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...